



Spero Therapeutics to Present at Upcoming September Investor Conferences

CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference to be held in New York, NY, September 9th - 11th, 2024. He will also participate in a fireside chat and be available for one-on-one meetings at Cantor's Global Healthcare Conference in New York, NY, September 17th - 19th, 2024. Details are as follows:

H.C. Wainwright 26th Annual Global Investment Conference

Presentation Date: September 10, 2024
Time: 4:00 - 4:30 PMET
Webcast link: [Company Presentation](#)

Cantor's Global Healthcare Conference

Analyst Fireside Chat: September 17, 2024
Time: 1:20 - 1:50 PMET
Webcast link: [Fireside Chat](#)

The webcasts may also be accessed through Spero's website on the "Events and Presentations" page (<https://www.sperotherapeutics.com/investor-relations>). A replay will be available on the website following the conclusion of the event.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections. For more information, visit <https://sperotherapeutics.com>.

Investor Relations Contact:

Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries:

media@sperotherapeutics.com



9/4/2024 4:05:00 PM